Iteos Therapeutics Inc Cash Flow Conversion Efficiency
Iteos Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Iteos Therapeutics Inc (ITOS) has a cash flow conversion efficiency ratio of -0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.45 Million) by net assets ($493.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Iteos Therapeutics Inc (2018–2024)
Cash flow conversion efficiency of Iteos Therapeutics Inc from 2018 to 2024. This chart illustrates how Iteos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ITOS live share price for real-time trading data and today's change.
Iteos Therapeutics Inc Cash Flow Conversion Ratio Explained
Iteos Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Iteos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iteos Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Iteos Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PTC India Limited
NSE:PTC
|
0.317x |
|
Vinci Partners Investments Ltd
NASDAQ:VINP
|
0.031x |
|
Bumble Inc
NASDAQ:BMBL
|
0.087x |
|
Shenzhen Haoningda Meters Co Ltd
SHE:002356
|
-0.013x |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
0.072x |
|
Shandong Teamgene Technology Co. Ltd. A
SHG:603151
|
N/A |
|
Heren Health Co Ltd
SHE:300550
|
0.007x |
|
Tengda Construction Group Co Ltd
SHG:600512
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Iteos Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Iteos Therapeutics Inc from 2018 to 2024. Review ITOS cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $590.29 Million | $-98.18 Million | -0.166x | +7.79% |
| 2023-12-31 | $575.23 Million | $-103.76 Million | -0.180x | -7.60% |
| 2022-12-31 | $663.33 Million | $-111.19 Million | -0.168x | -118.06% |
| 2021-12-31 | $552.82 Million | $513.14 Million | 0.928x | +1291.61% |
| 2020-12-31 | $323.20 Million | $-25.18 Million | -0.078x | +94.73% |
| 2019-12-31 | $15.67 Million | $-23.14 Million | -1.477x | -16.43% |
| 2018-12-31 | $15.05 Million | $-19.10 Million | -1.269x | -- |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more